Assembly Biosciences Inc. (NASDAQ: ASMB) announced the pricing of an underwritten offering of 3,358,602 shares of common stock at $26.50 per share and pre-funded warrants to purchase up to 415,000 shares at $26.499 per warrant. The biotechnology company expects gross proceeds of approximately $100 million before deducting underwriting discounts and other offering expenses.

The offering includes participation from new and existing investors, including Gilead Sciences Inc., Commodore Capital, Farallon Capital Management, Seven Fleet Capital, Sirenia Capital Management LP, Columbia Threadneedle Investments, Paradigm BioCapital Advisors, Squadron Capital Management and other healthcare-focused investors.

Assembly Biosciences has granted underwriters a 30-day option to purchase up to an additional 566,040 shares at the offering price, less underwriting discounts and commissions. The offering is expected to close on or about May 26, 2026, subject to customary closing conditions.

The South San Francisco-based company plans to use net proceeds to fund clinical development of pipeline candidates and for general corporate purposes. Assembly Biosciences develops therapeutics targeting viral and liver diseases.

Guggenheim Securities and UBS Investment Bank are serving as joint book-running managers for the offering, with Mizuho also acting as a book-running manager. H.C. Wainwright & Co. is acting as lead manager.

A shelf registration statement relating to the securities was filed with the Securities and Exchange Commission and declared effective on March 27, 2026, according to the company's statement.